The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
Recruiting · NCT07604467 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Medical Centre Ljubljana
View the official record on ClinicalTrials.gov →What this trial is about
The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Minimum age 18 years
- Established TTS per InterTak registry criteria
- Signed consent form
Exclusion criteria
- Patients under the age of 18 years
- Ischemic heart disease with at least one complete total occlusion
- Other concurrent cardiomyopathies
- Active infectious myocarditis
- obstructive coronary artery disease
- Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event
- Previous interventional coronary artery procedure in the last 6 months before TTS acute event
- Significant valvular heart disease
- Significant peripheral artery occlusive disease
- Active or remitted hematologic malignancy
- Patients receiving immunosuppressive therapy
- Significant comorbiditeis affecting patients survival (malignancy)
- Failure to obtain freely given, informed consent form.
Where it is running
1 location listed.
- Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia - Ljubljana, Ljubljana, Slovenia